Torrent Pharmaceuticals Limited
TORNTPHARM
Classement en actions
#1200
Torrent Pharmaceuticals Limited operates as a global pharmaceutical entity,... Torrent Pharmaceuticals Limited operates as a global pharmaceutical entity, managing the entire process from the discovery and development of generic drug formulations to their production and distribution. Its commercial activities extend across key markets such as India, the United States, Germany, and Brazil, alongside various other international territories. The company boasts a broad product catalog, offering treatments for a wide array of medical conditions. This includes therapies for cardiovascular diseases, central nervous system disorders, gastrointestinal issues, women's health concerns, diabetes, pain management, gynecological ailments, oncology, and anti-infective medications. Additionally, Torrent Pharma supplies essential vitamins, minerals, and other nutritional supplements. Beyond its proprietary offerings, the firm also provides contract manufacturing services to other companies. During the COVID-19 pandemic, it demonstrated its commitment by securing licensing agreements for crucial treatments like Baricitinib, Molnupiravir, and Paxlovid. Established in 1959, the company originally operated under the name Trinity Laboratories before officially becoming Torrent Pharmaceuticals Limited in 1971. Its corporate headquarters are located in Ahmedabad, India. Ultimately, Torrent Pharmaceuticals Limited functions as a subsidiary of Torrent Investments Private Limited.
Prix de l'action
$50.31
Dernière synchronisation: 2026-10-19
Capitalisation boursière
$19.14B
Changement (1 jour)
-0.14%
Changement (1 an)
23.32%
Pays
IN
Échange Torrent Pharmaceuticals Limited (TORNTPHARM)
Catégorie
Healthcare
Bénéfices pour Torrent Pharmaceuticals Limited (TORNTPHARM)
Bénéfices en Jun 2026 TTM : $316.40M
Selon les derniers rapports financiers de Torrent Pharmaceuticals Limited, les bénéfices actuels de l'entreprise sont de $316.40M. En 2024, l'entreprise a réalisé un bénéfice de $282.08M, une augmentation par rapport à celui de 2023 qui était de $224.77M. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Torrent Pharmaceuticals Limited de 2005 à 2026
Bénéfices à la fin de chaque année
| Année | Bénéfices | Changez |
|---|---|---|
| 2026 (TTM) | $316.40M | 1.24% |
| 2025 | $312.51M | 10.79% |
| 2024 | $282.08M | 25.50% |
| 2023 | $224.77M | 39.18% |
| 2022 | $161.50M | -22.54% |
| 2021 | $208.49M | 32.37% |
| 2020 | $157.51M | 94.73% |
| 2019 | $80.88M | -43.43% |
| 2018 | $142.99M | -14.78% |
| 2017 | $167.79M | -52.57% |
| 2016 | $353.73M | 134.86% |
| 2015 | $150.61M | -3.94% |
| 2014 | $156.79M | 46.48% |
| 2013 | $107.04M | 51.35% |
| 2012 | $70.72M | -8.03% |
| 2011 | $76.89M | -0.54% |
| 2010 | $77.31M | 104.22% |
| 2009 | $37.86M | 1.60% |
| 2008 | $37.26M | 48.13% |
| 2007 | $25.15M | 44.18% |
| 2006 | $17.45M | 33.96% |
| 2005 | $13.02M | 0.00% |
Bénéfices des entreprises similaires ou concurrentes
| Entreprise | Bénéfices | Différence de bénéfices | Pays |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 457.70% |
IN
|
